As Valeant Pharmaceuticals Intl Inc (NYSE: VRX) continues to face legal battles on several fronts and Relypsa Inc (Nasdaq: RLYP) struggles to ramp sales of its new drug, Irina Rivkind Koffler of Mizuho explains why she remains bearish on both companies. Irina Rivkind Koffler, a prominent healthcare analyst with
May 31, 2016